BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12700348)

  • 1. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.
    Scobie HM; Rainey GJ; Bradley KA; Young JA
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5170-4. PubMed ID: 12700348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.
    Chen KH; Liu S; Bankston LA; Liddington RC; Leppla SH
    J Biol Chem; 2007 Mar; 282(13):9834-9845. PubMed ID: 17251181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The receptors that mediate the direct lethality of anthrax toxin.
    Liu S; Zhang Y; Hoover B; Leppla SH
    Toxins (Basel); 2012 Dec; 5(1):1-8. PubMed ID: 23271637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting.
    Chen KH; Liu S; Leysath CE; Miller-Randolph S; Zhang Y; Fattah R; Bugge TH; Leppla SH
    J Biol Chem; 2016 Oct; 291(42):22021-22029. PubMed ID: 27555325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen.
    Wigelsworth DJ; Krantz BA; Christensen KA; Lacy DB; Juris SJ; Collier RJ
    J Biol Chem; 2004 May; 279(22):23349-56. PubMed ID: 15044490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor.
    Lacy DB; Wigelsworth DJ; Scobie HM; Young JA; Collier RJ
    Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6367-72. PubMed ID: 15079089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo.
    Liu S; Crown D; Miller-Randolph S; Moayeri M; Wang H; Hu H; Morley T; Leppla SH
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12424-9. PubMed ID: 19617532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and purification of functional human anthrax toxin receptor (ATR/TEM8) binding domain from Escherichia coli.
    Ding Z; Bradley KA; Amin Arnaout M; Xiong JP
    Protein Expr Purif; 2006 Sep; 49(1):121-8. PubMed ID: 16798009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallization and preliminary X-ray analysis of the vWA domain of human anthrax toxin receptor 1.
    Cai C; Zhao Y; Tong X; Fu S; Li Y; Wu Y; Li X; Lou Z
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Jan; 67(Pt 1):64-7. PubMed ID: 21206026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the interaction between anthrax toxin and its cellular receptors.
    Liu S; Leung HJ; Leppla SH
    Cell Microbiol; 2007 Apr; 9(4):977-87. PubMed ID: 17381430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin.
    Martchenko M; Jeong SY; Cohen SN
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15583-8. PubMed ID: 20713715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin.
    Fu S; Tong X; Cai C; Zhao Y; Wu Y; Li Y; Xu J; Zhang XC; Xu L; Chen W; Rao Z
    PLoS One; 2010 Jun; 5(6):e11203. PubMed ID: 20585457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors.
    Cai C; Che J; Xu L; Guo Q; Kong Y; Fu L; Xu J; Cheng Y; Chen W
    PLoS One; 2011; 6(6):e20646. PubMed ID: 21674060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor.
    Dawson RM
    J Pharmacol Toxicol Methods; 2009; 59(1):50-5. PubMed ID: 19049885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of domain 4 of the anthrax toxin protective antigen and the effect of the VWA domain of CMG2 on stability.
    Mamillapalli S; Miyagi M; Bann JG
    Protein Sci; 2017 Feb; 26(2):355-364. PubMed ID: 27874231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between anthrax toxin receptors and protective antigen.
    Scobie HM; Young JA
    Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-specific requirements for anthrax toxin delivery into cells.
    Rainey GJ; Wigelsworth DJ; Ryan PL; Scobie HM; Collier RJ; Young JA
    Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13278-83. PubMed ID: 16141341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2.
    Verma A; Moayeri M; Mocca CP; O'Mard D; Ma Q; Leppla SH; Burns DL
    Vaccine; 2022 Jul; 40(32):4318-4321. PubMed ID: 35710508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor.
    Li L; Guo Q; Liu J; Zhang J; Yin Y; Dong D; Fu L; Xu J; Chen W
    Toxins (Basel); 2016 Jan; 8(1):. PubMed ID: 26805881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.
    Rogers MS; Cryan LM; Habeshian KA; Bazinet L; Caldwell TP; Ackroyd PC; Christensen KA
    PLoS One; 2012; 7(6):e39911. PubMed ID: 22768167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.